NCT07152210 is a NA clinical trial of CAR-T in Colorectal Cancer (CRC), sponsored by Guangzhou Bio-gene Technology Co., Ltd.

Who is sponsoring NCT07152210?

NCT07152210 is sponsored by Guangzhou Bio-gene Technology Co., Ltd.

What drugs are being tested in NCT07152210?

Interventions in NCT07152210: CAR-T.

What condition does NCT07152210 study?

NCT07152210 studies Colorectal Cancer (CRC).

Is NCT07152210 still recruiting?

NCT07152210 is currently recruiting now. Last updated 3 September 2025.

Last reviewed 2025-09-03 · How we verify

NCT07152210

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study on the Safety and Preliminary Efficacy of CDH17/GUCY2C CAR-T in the Treatment of Patients With Advanced Colorectal Cancer

Recruiting now NA Last updated 3 September 2025

What this trial tests

NA trial testing CAR-T in Colorectal Cancer (CRC) in 20 participants. Currently enrolling.

Timeline

1 September 2025

Primary endpoint
31 December 2028

31 December 2028

Quick facts

Lead sponsor	Guangzhou Bio-gene Technology Co., Ltd
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 September 2025
Primary completion	31 December 2028
Estimated completion	31 December 2028
Sites	1 location across China

Drugs / interventions tested

CAR-T — full drug profile →

Conditions studied

Colorectal Cancer (CRC) — all drugs for Colorectal Cancer (CRC) →

Sponsor

Guangzhou Bio-gene Technology Co., Ltd — full company profile →

Who can join

Adults 18 to 70, any sex, with Colorectal Cancer (CRC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a single-arm, single-center investigator-initiated trial (IIT) designed to evaluate the safety and preliminary efficacy of CDH17/GUCY2C CAR-T cell therapy in patients with advanced colorectal cancer, as well as to assess its pharmacodynamic (PD) and pharmacokinetic (PK) profiles.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Cadherin 17 and digestive cancers: from diagnostic to therapeutic opportunities.
Fernandez B, Lopez L, Matis T, Dabernat S, et al · · 2026 · PMID 41928253 · DOI 10.1186/s13046-026-03693-8
Immunotherapy for microsatellite-stable colorectal cancer: overcoming resistance and exploring novel therapeutic strategies.
Kim SY. · · 2026 · PMID 41802306 · DOI 10.3393/ac.2025.01354.0193

Verify or expand the search:

Other trials of CAR-T

Trials testing the same drug.

NCT07370064 — Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia · Phase 1, PHASE2 · not yet recruiting
NCT07338357 — Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML · EARLY_PHASE1 · not yet recruiting
NCT07441291 — CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT · Phase 3 · recruiting
NCT07152236 — Clinical Study on the Safety and Efficacy of B7H3 CAR T Cells in Patients With B7H3 Positive Solid Tumors · NA · recruiting
NCT07152223 — Clinical Study on the Safety and Efficacy of CD19-BCMA CAR-T Cell Therapy for Connective Tissue Diseases · NA · recruiting

Other recruiting trials for Colorectal Cancer (CRC)

Currently open trials in the same condition.

NCT07448142 — Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer · Phase 2 · recruiting
NCT07223047 — A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agent · Phase 1, PHASE2 · recruiting
NCT07106892 — Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects Wit · Phase 2 · recruiting
NCT07046468 — Smart Pill for Measuring Gut Health in Colon Inflammation and Colon Cancer · recruiting
NCT07020468 — Neoadjuvant Therapy （NALIRIFOX） for Locally Advanced Colon and Upper Rectal Cancer · Phase 4 · active not recruiting

Other Guangzhou Bio-gene Technology Co., Ltd trials

Trials by the same sponsor.

NCT07195617 — Clinical Study on Evaluating the Safety and Effectiveness of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Mult · NA · not yet recruiting
NCT07196124 — BCMA/GPRC5D CAR-T Therapy for Multiple Myeloma · EARLY_PHASE1 · not yet recruiting
NCT07196111 — BAFFR CAR-T Treatment for Relapsed/Refractory B-cell Tumors · EARLY_PHASE1 · not yet recruiting
NCT07123662 — γδ T Cell Therapy for Relapse Prevention in High-Risk AML Post-Transplant · EARLY_PHASE1 · not yet recruiting
NCT07152236 — Clinical Study on the Safety and Efficacy of B7H3 CAR T Cells in Patients With B7H3 Positive Solid Tumors · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07152210 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangzhou Bio-gene Technology Co., Ltd
Last refreshed: 3 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07152210.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing